Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population

References

• Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434–437.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Surveillance epidemiology and end results. Cancer stat facts: Colorectal cancer 2020. [cited 2020 Aug 31]. Available from: https://seer.cancer.gov/statfacts/html/colorect.html
   Google Scholar
• Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2016;315(23):2564–2575.
   PubMed Web of Science ®Google Scholar
• Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–281.
   PubMed Web of Science ®Google Scholar
• D'Andrea E, Ahnen DJ, Sussman DA, et al. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality. Cancer Med. 2020;9(2):824–836.
   PubMed Web of Science ®Google Scholar
• Limburg P, Saoud L, Borah BJ, et al. Higher impact on clinical outcomes from delays in colorectal cancer screening with the fecal immunochemical test vs multitarget stool DNA: CRC-AIM microsimulation model results. Gastroenterology. 2020;158(6):S-1176.
   PubMed Web of Science ®Google Scholar
• Ran T, Cheng CY, Misselwitz B, et al. Cost-effectiveness of colorectal cancer screening strategies-a systematic review. Clin Gastroenterol Hepatol. 2019;17(10):1969–1981.
   PubMed Web of Science ®Google Scholar
• Zhong GC, Sun WP, Wan L, et al. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis. Gastrointest Endosc. 2020;91(3):684–6975.
   PubMed Web of Science ®Google Scholar
• Peterse EFP, Meester RGS, de Jonge L, et al. Comparing the cost-effectiveness of innovative colorectal cancer screening tests. J Natl Cancer Inst. 2021;113(2):154–161.
   PubMedGoogle Scholar
• National Cancer Institute. Cancer intervention and surveillance modeling network. CISNET model registry 2020. [cited 2020 Mar 29]. Available from: https://resources.cisnet.cancer.gov/registry/site-summary/colorectal/
   Google Scholar
• Naber SK, Knudsen AB, Zauber AG, et al. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLOS One. 2019;14(9):e0220234.
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. Gastroenterology. 2016;151(3):427–439.
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Mannalithara A, Brill JV, et al. Contrasting effectiveness and cost-effectiveness of colorectal cancer screening under commercial insurance vs. Medicare. Am J Gastroenterol. 2018;113(12):1836–1847.
   PubMed Web of Science ®Google Scholar
• Vijan S, Hwang EW, Hofer TP, et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med. 2001;111(8):593–601.
   PubMed Web of Science ®Google Scholar
• Piscitello A, Saoud L, Fendrick AM, et al. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model. PLOS One. 2020;15(12):e0244431.
   PubMed Web of Science ®Google Scholar
• Description and validation of the novel colorectal cancer and adenoma incidence & mortality (CRC-AIM) microsimulation model. [Internet]. bioRxiv: 2020 [cited 2021 Apr 16]. Available from: https://www.biorxiv.org/content/https://doi.org/10.1101/2020.03.02.966838v1
   Google Scholar
• Cooper GS, Grimes A, Werner J, et al. editors. Barriers to colonoscopic follow-up after positive fecal immunochemical testing or multitarget stool DNA testing, Digestive Disease Week; 2020; Chicago (IL).
   Google Scholar
• Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575–582.
   PubMedGoogle Scholar
• Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive services task force. JAMA. 2016;315(23):2595–2609.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & medicaid services. Physician fee schedule 2020. [cited 2020 Aug 20]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
   Google Scholar
• Ladabaum U, Levin Z, Mannalithara A, et al. Colorectal testing utilization and payments in a large cohort of commercially insured US adults. Am J Gastroenterol. 2014;109(10):1513–1525.
   PubMed Web of Science ®Google Scholar
• Hathway JM, Miller-Wilson LA, Jensen IS, et al. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ. 2020;23(6):581–592.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128.
   PubMed Web of Science ®Google Scholar
• St. Louis Fed. Consumer price index for all urban consumers: medical care in U.S. city average (CPIMEDSL) 2020. [2020 Sep 18]. Available from: https://fred.stlouisfed.org/series/CPIMEDSL
   Google Scholar
• Szende A, Janssen B, Cabases J (editors). Self-reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer; 2014.
   Google Scholar
• Goede SL, Rabeneck L, Van Ballegooijen M, et al. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLOS One. 2017;12(3):e0172864.
   PubMed Web of Science ®Google Scholar
• Weiser E, Parks PD, Swartz RK, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: real-world data from a large cohort of older adults. J Med Screen. 2021;28(1):18–24.
   PubMed Web of Science ®Google Scholar
• Akram A, Juang D, Bustamante R, et al. Replacing the guaiac fecal occult blood test with the fecal immunochemical test increases proportion of individuals screened in a large healthcare setting. Clin Gastroenterol Hepatol. 2017;15(8):1265–1270 e1.
   PubMed Web of Science ®Google Scholar
• Hassan C, Giorgi Rossi P, Camilloni L, et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther. 2012;36(10):929–940.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–1258.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Singal AG, Gupta S, Skinner CS, et al. Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion: a randomized clinical trial. JAMA. 2017;318(9):806–815.
   PubMed Web of Science ®Google Scholar
• Joseph DA, King JB, Richards TB, et al. Use of colorectal cancer screening tests by state. Prev Chronic Dis. 2018;15:E80.
   PubMed Web of Science ®Google Scholar
• Jones RM, Devers KJ, Kuzel AJ, et al. Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. Am J Prev Med. 2010;38(5):508–516.
   PubMed Web of Science ®Google Scholar
• May FP, Yano EM, Provenzale D, et al. Barriers to follow-up colonoscopies for patients with positive results from fecal immunochemical tests during colorectal cancer screening. Clin Gastroenterol Hepatol. 2019;17(3):469–476.
   PubMed Web of Science ®Google Scholar
• Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(12):1645–1658.
   PubMed Web of Science ®Google Scholar
• Liang PS, Wheat CL, Abhat A, et al. Adherence to competing strategies for colorectal cancer screening over 3 years. Am J Gastroenterol. 2016;111(1):105–114.
   PubMed Web of Science ®Google Scholar
• Prince M, Lester L, Chiniwala R, et al. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients. World J Gastroenterol. 2017;23(3):464–471.
   PubMed Web of Science ®Google Scholar
• Selby K, Jensen CD, Levin TR, et al. Program components and results from an organized colorectal cancer screening program using annual fecal immunochemical testing. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)31372-0.
   Web of Science ®Google Scholar
• Issaka RB, Akinsoto NO, Strait E, et al. Effectiveness of a mailed fecal immunochemical test outreach: a Medicare advantage pilot study. Therap Adv Gastroenterol. 2020;13:175628482094538.
   Web of Science ®Google Scholar
• Kisiel JB, Limburg PJ. Colorectal Cancer Screening With the Multitarget Stool DNA Test. Am J Gastroenterol. 2020;115(11):1737–1740.
   PubMed Web of Science ®Google Scholar
• O'Hanlon C, Huang C, Sloss E, et al. Comparing VA and non-VA quality of care: a systematic review. J Gen Intern Med. 2017;32(1):105–121.
   PubMed Web of Science ®Google Scholar
• Coronado GD, Green BB, West II, et al. Direct-to-member mailed colorectal cancer screening outreach for Medicaid and Medicare enrollees: implementation and effectiveness outcomes from the BeneFIT study. Cancer. 2020;126(3):540–548.
   PubMed Web of Science ®Google Scholar
• Finney Rutten LJ, Jacobson DJ, Jenkins GD, et al. Colorectal cancer screening completion: an examination of differences by screening modality. Prev Med Rep. 2020;20:101202.
   PubMedGoogle Scholar
• Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164(7):456–463.
   PubMed Web of Science ®Google Scholar